Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Androgens, Estrogens, and the Ultimate Height in XO Gonadal Dysgenesis

Androgens, Estrogens, and the Ultimate Height in XO Gonadal Dysgenesis Abstract • We observed 40 patients with 45,X gonadal dysgenesis from the age of 13 to 15 years until the age of 18 to 21 years. The ultimate height of the 12 nontreated patients was 143.2 cm. Of 15 patients treated with nandrolone phenpropionate or methandrostenolone, the ultimate height was 143.3 cm, and of 13 patients treated with ethinyl estradiol, the height reached was 144.1 cm. The mean height of ten patients first seen at the age of 25 to 31 years was 140.1 cm. The mean height at any age was almost identical in all the groups. The growth velocity was somewhat accelerated by anabolic steroids and to a lesser extent, by estrogens only during the first year of therapy, and this did not influence the ultimate height. We saw no deleterious effects of the estrogens. In all the groups, there were patients who grew for some time at rates of up to 4 to 6 cm/yr. Therefore, long-term follow-up studies are needed for the evaluation of the effects of any treatment. (Am J Dis Child 131:648-649, 1977) References 1. Tikhonov VA, Liberman LL: The growth and skeletal development in gonadal dysgenesis . Probl Endokrinol 3:38-42, 1966. 2. Almqvist S, Lindsten J, Lindvall N: Linear growth, sulfation factor activity and chromosome constitution in 22 subjects with Turner's syndrome . Acta Endocrinol 42:168-186, 1963. 3. Lindsten J: The Nature and Origin of X-Chromosome Aberrations in Turner's Syndrome: A Cytogenetical and Clinical Study of 57 Patients . Stockholm, Almqvist, 1963. 4. Snider M, Solomon IL: Ultimate height in chromosomal gonadal dysgenesis without androgen therapy . Am J Dis Child 127:673-674, 1974. 5. Engel E, Forbes AP: Cytogenetic and clinical findings in 48 patients with congenitally defective or absent ovaries . Medicine 44:135-164, 1965.Crossref 6. Siegel S: Nanparametric Statistics . New York, McGraw-Hill Book Co Inc, 1956, pp 116-127. 7. Johanson AJ, Brasel JA, Blizzard RM: Growth in patients with gonadal dysgenesis receiving fluoxymestrone . J Pediatr 75:1015-1021, 1969.Crossref 8. Rosenbloom AL, Frias JL: Oxandrolone for growth promotion in Turner syndrome . Am J Dis Child 125:385-387, 1973. 9. Prader A: The influence of anabolic steroids on growth . Acta Endocrinol 63( (suppl) ):78-88, 1962. 10. Blaim A: Wplyw androgenów na wzrost u dzieci z zespolem Turnera . Endokrynol Pol 15:529-534, 1964. 11. Brook CGD, Mürset G, Zachman M, et al: Growth in children with 45,XO Turner's syndrome . Arch Dis Child 49:789-795, 1974.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Diseases of Children American Medical Association

Androgens, Estrogens, and the Ultimate Height in XO Gonadal Dysgenesis

American Journal of Diseases of Children , Volume 131 (6) – Jun 1, 1977

Loading next page...
 
/lp/american-medical-association/androgens-estrogens-and-the-ultimate-height-in-xo-gonadal-dysgenesis-5Ky0obBZnQ
Publisher
American Medical Association
Copyright
Copyright © 1977 American Medical Association. All Rights Reserved.
ISSN
0002-922X
DOI
10.1001/archpedi.1977.02120190042008
Publisher site
See Article on Publisher Site

Abstract

Abstract • We observed 40 patients with 45,X gonadal dysgenesis from the age of 13 to 15 years until the age of 18 to 21 years. The ultimate height of the 12 nontreated patients was 143.2 cm. Of 15 patients treated with nandrolone phenpropionate or methandrostenolone, the ultimate height was 143.3 cm, and of 13 patients treated with ethinyl estradiol, the height reached was 144.1 cm. The mean height of ten patients first seen at the age of 25 to 31 years was 140.1 cm. The mean height at any age was almost identical in all the groups. The growth velocity was somewhat accelerated by anabolic steroids and to a lesser extent, by estrogens only during the first year of therapy, and this did not influence the ultimate height. We saw no deleterious effects of the estrogens. In all the groups, there were patients who grew for some time at rates of up to 4 to 6 cm/yr. Therefore, long-term follow-up studies are needed for the evaluation of the effects of any treatment. (Am J Dis Child 131:648-649, 1977) References 1. Tikhonov VA, Liberman LL: The growth and skeletal development in gonadal dysgenesis . Probl Endokrinol 3:38-42, 1966. 2. Almqvist S, Lindsten J, Lindvall N: Linear growth, sulfation factor activity and chromosome constitution in 22 subjects with Turner's syndrome . Acta Endocrinol 42:168-186, 1963. 3. Lindsten J: The Nature and Origin of X-Chromosome Aberrations in Turner's Syndrome: A Cytogenetical and Clinical Study of 57 Patients . Stockholm, Almqvist, 1963. 4. Snider M, Solomon IL: Ultimate height in chromosomal gonadal dysgenesis without androgen therapy . Am J Dis Child 127:673-674, 1974. 5. Engel E, Forbes AP: Cytogenetic and clinical findings in 48 patients with congenitally defective or absent ovaries . Medicine 44:135-164, 1965.Crossref 6. Siegel S: Nanparametric Statistics . New York, McGraw-Hill Book Co Inc, 1956, pp 116-127. 7. Johanson AJ, Brasel JA, Blizzard RM: Growth in patients with gonadal dysgenesis receiving fluoxymestrone . J Pediatr 75:1015-1021, 1969.Crossref 8. Rosenbloom AL, Frias JL: Oxandrolone for growth promotion in Turner syndrome . Am J Dis Child 125:385-387, 1973. 9. Prader A: The influence of anabolic steroids on growth . Acta Endocrinol 63( (suppl) ):78-88, 1962. 10. Blaim A: Wplyw androgenów na wzrost u dzieci z zespolem Turnera . Endokrynol Pol 15:529-534, 1964. 11. Brook CGD, Mürset G, Zachman M, et al: Growth in children with 45,XO Turner's syndrome . Arch Dis Child 49:789-795, 1974.Crossref

Journal

American Journal of Diseases of ChildrenAmerican Medical Association

Published: Jun 1, 1977

References